Abstract
Only a handful of interventions are known to prevent the progression of chronic kidney disease (CKD) and the need for kidney replacement therapy. This exclusive list previously only featured angiotensin converting enzyme inhibitors and angiotensin receptor blockers but recently was expanded to include sodium glucose cotransporter 2 (SGLT2) inhibitors. These medications also reduce the risk of cardiovascular (CV) events in patients with kidney disease. Despite current, effective treatments, many patients will continue to suffer from kidney failure and an excess of CV events and the need for additional therapies remains.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
